The Role of Vitamin D3 in Pediatric Bronchiectasis Severity

The Role of Vitamin D3 in Pediatric Bronchiectasis Severity( CF Versus Non CF Bronchioectasis)

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04411901

Enrollment

Registered

2020-06-02

Start date

2018-03-01

Completion date

2019-03-20

Last updated

2020-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis and Non CF Bronchiectasis

Brief summary

Vitamin D3 therapy was effective in decreasing the frequency of pulmonary exacerbations and preserving lung functions , thereby improving the disease severity even more in non CF than CF bronchiectasis patients

Detailed description

Objectives: To compare the effect of vitamin D3 on modifying the disease severity in CF and non CF bronchiectasis pediatric patients. Patients and Methods: This was a randomized clinical trial evaluating the role of oral vitamin D3 supplementation for 6 months in forty patients with CF and non CF bronchiectasis under the age of 18 years with vitamin D deficiency or insufficiency . The primary outcome was to reach the sufficient Vitamin D level. The secondary outcome was to follow up the frequency of pulmonary exacerbations and lung function after vitamin D3 supplementation.

Interventions

DRUGCholecalciferol (vitaminD3)

Theraputic vitamin D3 for CF and non CF bronchiectasis children

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Years to 17 Years

Healthy volunteers

Inclusion criteria

* ages less than 18 years . * Patients with documented diagnosis of CF (by the presence of a twice positive sweat chloride test and or paired CFTR DNA genetic mutations). * Patients with non CF bronchiectasis diagnosed clinically and radiologically ( sweat chloride test negative) with a high resolution CT-confirmed diagnosis and clinical history consistent with bronchiectasis . * Vitamin D deficient or insufficient CF and non CF bronchiectasis patients

Exclusion criteria

if they had * sufficient Vitamin D level . * chronic lung diseases other than CF and non CF bronchiectasis , liver or renal diseases. * reported taking vitamin-D supplements or steroid therapy in the last 6 weeks.

Design outcomes

Primary

Measure	Time frame	Description
reach sufficient vitamin D level	6 months	vitamin D more than 30 ng/dl
decrease disease severity	6 months	decrease excerbations and increase lung function

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026